and drug interactions, and reduced synthesis of all vitamin K-dependent proteins. 3 Therefore, different strategies have been developed, including novel oral anticoagulants (NOAC) and left atrial appendage (LAA) occlusion devices. Despite these developments, the best strategy for stroke prevention remains to be fully elucidated, especially in the elderly.
Several NOACs are available that offer potential advantages over warfarin. Randomized controlled trials (RCTs) have shown that these medications are at least as safe and effective as warfarin for prevention of stroke and systemic embolism (SSE) in patients with NVAF. 4 The LAA is a site of major blood stasis during AF increasing the risk of thrombus formation and stroke, thus it has been a target for emerging technologies to prevent this disabling complication. Percutaneous LAA occlusion devices have been developed to overcome the aforementioned challenges. 5, 6 The only reported RCTs of LAA closure are the Watchman LAA System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT-AF) and the Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trials evaluating the Watchman device (Boston Scientific, Natick, MA). 7, 8 These trials have demonstrated noninferiority to adjusted-dose warfarin therapy.
Despite these advances, it is still uncertain what is the best strategy for stroke prevention in NVAF. To better assess the clinical implications of these strategies, we carried out a systematic review of the literature and a meta-analysis of randomized, 
WHAT IS KNOWN
• Stroke prevention is important in the management of atrial fibrillation to reduce morbidity and mortality.
• Warfarin, novel oral anticoagulants, and left atrial appendage occlusion devices are the options available for stroke prevention in nonvalvular atrial fibrillation.
WHAT THE STUDY ADDS
• This meta-analysis confirms that stroke prevention with novel oral anticoagulants is superior than warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
• Stroke prevention with novel oral anticoagulants is superior than warfarin for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
• The Watchman left atrial appendage occlusion device is a reasonable noninferior alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation.
clinical trials of NOACs and Watchman device compared to therapy with warfarin for the prevention of stroke in patients with NVAF, including a subgroup analysis of the elderly population.
Methods

Search Strategy
We conducted electronic database searches of phase III RCTs, through a computerized literature search of PubMed, CENTRAL, EMBASE, The Cochrane Central Register of Controlled Trials, the ClinicalTrials.gov Website, Google Scholar databases, the scientific session abstracts in Circulation, Journal of the American College of Cardiology, European Heart Journal, and American Journal of Cardiology from January 1990 to April 2015. Oral presentations or expert slide presentations were included (searched on the TCT (www.tctmd.com), EuroPCR (www.europcr.com), ACC (www.acc. org), AHA (www.aha.org), and ESC (www.escardio.org). We also performed manual searches of the reference lists of each study, reviews, editorials, letters, food and drug administration reports, and related conference proceedings, as well as Boston Scientific Watchman device reports. Information was last assessed as up-todate: April 18th 2015.
Search terms keywords included: randomized controlled trial, atrial fibrillation, nonvalvular atrial fibrillation, stroke, apixaban, rivaroxaban, dabigatran, edoxaban, oral factor Xa inhibitor, oral thrombin inhibitor, warfarin, Watchman, Watchman device, left atrial appendage occlusion, left atrial appendage occlusion device, and combinations of these terms. No language restrictions were enforced. Search was further limited to studies performed in humans.
Seven phase III RCTs were available comparing the efficacy and safety of NOACs or Watchman device with warfarin for stroke prevention in patients with NVAF: Randomized Evaluation of LongTerm Anticoagulation Therapy (RE-LY; dabigatran), 9 Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), 10 Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 11 ENGAGE AF-TIMI 48 study (Edoxaban), 12 Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation (J-ROCKET AF), 13 PROTECT-AF, 7 and PREVAIL. 8 An additional search limited to the elderly population (≥75 years of age) with NVAF was done using the same criteria as above. Six phase III RCTs were found comparing NOACs and Watchman device to warfarin for stroke prevention in this population. The trials that had this information available were RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF-TIMI 48, PROTECT-AF, and PREVAIL. [9] [10] [11] 14 Elderly data for the Watchman device trials was only available for patients ≥72 years old (Boston Scientific device report).
Inclusion Criteria
The PRISMA statement for reporting systematic reviews and metaanalyses of RCTs was applied to the methods for this study. 15 Studies included were required to meet the following specifications: (1) RCT design, (2) evaluation of patients with NVAF only, and (3) inclusion of subjects randomized only to NOACs or Watchman device versus warfarin. Two reviewers D.F.B. and P.V.S. independently extracted data from identified RCTs. Disagreements were resolved by consensus or, if necessary, by a third party N.C.
Study End Points
The primary end point was the incidence of SSE. The secondary end point was all-cause mortality. The safety end point was adjudicated major bleeding during treatment or device-/procedure-related complications (Table 1) .
Statistical Analysis
Data was summarized across treatment arms using the odds ratio (OR) and 95% confidence intervals (CI) with a random-effects model. 16 The Cochran Q-test and the Higgins I 2 -test were used for heterogeneity testing. 17 In trials with multiple treatment arms, we collapsed the data to compute an effective size and variance. All participants in the NOACs and Device arms and all participants in the eligible control arms were pooled for analysis. To address publication bias, we used the funnel plots. 18 If any bias was observed, further bias quantification was measured using the Begg-Mazumdar test, 19 Egger test, 20 and the Duval and Tweedie trim and fill test. 21, 22 Sensitivity analyses were performed by using the one-study-out method, addressing the influence of each study by testing whether deleting each, in turn, would significantly change the pooled results of the meta-analysis. Chronological cumulative analyses were assessed in the Watchman left atrial appendage occlusion device (DEVICE) group to test if the effect size and precision shifts changes based on the procedure experience seen with time. 17 The statistical analysis was performed by the Comprehensive Meta-analysis version 2.0 software.
Results
Study Selection and Characteristics
The search strategy identified a total of 1069 potential articles (Figure 1 ). After removing duplicates and articles not meeting inclusion criteria, we screened 182 titles and abstracts. Of these, 12 were selected for further review of eligibility. Finally, 7 RCTs satisfied inclusion criteria, all of which were published in English. The baseline characteristics of the included trials are presented in Table 2 . Overall, the 7 RCTs enrolled a total of 73 978 patients. All the studies were phase III. The comparison groups included NOAC, the DEVICE and warfarin. The NOACs used in the RCTs were apixaban, rivaroxaban, dabigatran, and edoxaban. Duration of follow-up was >12 months in all trials. The anticoagulation strategy in the Watchman group was variable ( Figure 2 ). All 7 RCTs reported SSE and all-cause mortality for the primary end point. For the safety end point, the NOACs trials reported major bleeding, and DEVICE trials reported both major bleeding and device-/procedure-related complications. In terms of analysis, the different doses of the NOACs used in the trials were combined and analyzed as a single group.
Six RCTs were included in the analysis for the elderly ( Table 2 ). The 6 RCTs enrolled a total of 30 699 patients. All the studies were phase III. The comparison groups included NOAC, DEVICE, and warfarin. The NOACs used in the RCTs were rivaroxaban, dabigatran, apixaban, and edoxaban. The 6 RCTs reported SSE. No data were available for all-cause mortality and safety outcomes in the DEVICE group for the elderly, therefore, only the primary end point was analyzed in this subgroup.
Quantitative Data Synthesis
Primary End Point
There were a total of 2654 SSE in the entire group of patients: 3.5% (1487/42 998) in the NOAC and 3.4% (25/732) ‡2.5-mg doses were used in a subset of patients with ≥2 of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of ≥1.5 mg/dL. §For patients in either group, the dose was halved if any of the following characteristics were present at the time of randomization or during the study: estimated creatinine clearance of 30 to 50 mL/min, a body weight of ≥60 kg, or the concomitant use of verapamil or quinidine.
No difference was observed between DEVICE and warfarin ( Figure 3 ).
Secondary End Point
All-cause mortality was 5510 in the entire group of patients: 7.5% (3212/42 978) in the NOAC and 3.8% (28/732) in the DEVICE group. There was a significant difference favoring NOAC over warfarin for all cause mortality (OR, 0.89; 95% CI, 0.84-0.94; P<0.001). No difference was seen between DEVICE and warfarin ( Figure 4 ).
Safety End Point
There were 4085 cases of major bleeding or device-/procedure-related complications in all enrolled patients. The proportions of safety end points were 5% (2161/42 943) in the NOAC and 10.7% (78/732) in the DEVICE group. A significant difference favoring NOAC compared with warfarin was observed (OR, 0.79; 95% CI, 0.65-0.97; P=0.026). DEVICE was associated with more complications when compared with warfarin (OR, 1.85; 95% CI, 1.14-3.01; P=0.012; Figure 5 ).
Elderly-Primary End Point
Six RCTs reported outcomes in the elderly population (n=30 699 patients). There were a total of 1211 SSE in this group: 3.3% (544/16 280) in the NOAC and 11% (42/388) in the DEVICE group. There was a significant difference favoring NOAC over warfarin for SSE when compared with warfarin (OR, 0.77; 95% CI, 0.68-0.87; P≤0.001). No difference was seen between DEVICE and warfarin ( Figure 6 ).
Sensitivity Analysis
Sensitivity analysis involving the removal of each of the RCTs (only done for NOAC versus warfarin trials) one at a time demonstrated that RE-LY and ARISTOTLE influenced the summary risk estimates for SSE; if the studies are removed from the analysis the overall effect estimate becomes not significant (OR [ 
Bias
Funnel plot did not show asymmetry suggesting bias for all end points except for all-cause mortality ( Figure 7) . However, after quantifying the observed bias with others methods (Begg-Mazumdar, Egger and Duval, and Tweedie trim and fill test) there was no evidence of publication bias ( Figure III in the Data Supplement).
Discussion
This meta-analysis involved 73 978 patients for the general analysis and 30 699 for the elderly evaluation, providing a comprehensive assessment of the risk-benefit profile for the use of NOAC or Watchman device compared with warfarin for stroke prevention in NVAF.
The main finding of this meta-analysis is that stroke prevention in NVAF is superior with NOAC compared with warfarin, as it showed lower SSE and all cause mortality while having a better safety profile, whereas no difference was found between DEVICE and warfarin. Nonetheless, there is a marginal benefit to lower SSE and mortality in the DEVICE versus warfarin group, which is not statistically significant probably because of the limited sample size of the PROTECT-AF and PREVAIL trials. Consequently, it is important to highlight that the Watchman device is a reasonable noninferior alternative to warfarin for stroke prevention. However, it must be taken into account the higher rate of complications found in the DEVICE group (related mainly to bleeding, mostly during the first 45 days post implantation), which is probably determined by concomitant warfarin and aspirin use during this initial period. In addition, the need for dual antiplatelets 6 months post device implantation even if there is adequate LAA seal or the long-term addition of warfarin if no LAA seal is achieved, may weigh against preference for interventional LAA occlusion using this strategy in patients predisposed to bleeding (Figure 2) . About procedurerelated complications, the PROTECT-AF trial reported serious pericardial effusion (n=22), and device embolization (n=3), whereas the PREVAIL trial reported device embolization (n=2), arteriovenous fistula (n=1), cardiac perforation (n=1), and serious pericardial effusion (n=1).
Previous meta-analyses are available comparing NOACs with warfarin, illustrating similar results to our findings, including a favorable risk-benefit profile, with significant reductions in stroke and mortality. 4, 23, 24 However, to the best of our knowledge, this is the first time that the overall positive outcomes are reported to be dependent only by 2 trials (RE-LY and ARISTOTLE trials), as shown in the sensitivity study.
However, data on percutaneous devices for stroke prevention in NVAF is still limited. The use of this technology remains controversial because of scarce literature on efficacy and safety. The available data have compared observational studies, finding noninferiority of LAA closure compared with medical management with warfarin for stroke prevention in patients with NVAF. 25 Hence, this is the first attempt to compare the different strategies for stroke prevention in NVAF based on RCTs, including pharmacological and structural approaches, providing also insights into the elderly population. Therefore, this meta-analysis provides unique evidence supporting the concept that anticoagulation with NOACs is probably the best option available today for stroke prevention in NVAF in an average bleeding risk population. In addition, these results illustrate that the use of NOACs not only provides practical advantages over Watchman device but also is associated with an overall clinical benefit compared with both warfarin and the Watchman device, suggesting their cost effectiveness. Despite these results, further studies are needed, including RCTs and cost-effectiveness analysis comparing NOACs and the Watchman device to determine the best strategy for stroke prevention in NVAF.
Limitations
Our meta-analysis has some limitations given major differences between therapies, patient demographics, therapies, and trial characteristics that might affect outcomes not accounted for in this analysis. First, population characteristics were different among the single studies and because this is a studylevel meta-analysis, we were unable to confirm the overall results in specific subgroups of patients. Second, the definitions of composite end points for primary, secondary, and safety outcomes differed across trials. Third, we evaluated a pharmacological approach with a nonpharmacological strategy, which have largely different efficacy and safety profiles, therefore, the variability of approaches may be an important source of distortion in the observed point estimates. Fourth, the results of our meta-analysis are driven mainly by 5 large RCTs involving the NOACs, whereas fewer data are available on the Watchman device. 
